Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Receivables: 2015-2024

Historic Change in Receivables for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$27.9 million.

  • Intellia Therapeutics' Change in Receivables rose 91.28% to -$303,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 7.07%. This contributed to the annual value of -$27.9 million for FY2024, which is 185.47% down from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Change in Receivables is -$27.9 million, which was down 185.47% from $32.7 million recorded in FY2023.
  • Intellia Therapeutics' 5-year Change in Receivables high stood at $32.7 million for FY2023, and its period low was -$27.9 million during FY2024.
  • Moreover, its 3-year median value for Change in Receivables was $1.7 million (2022), whereas its average is $2.2 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first surged by 1,854.55% in 2022, then slumped by 185.47% in 2024.
  • Over the past 5 years, Intellia Therapeutics' Change in Receivables (Yearly) stood at -$2.5 million in 2020, then spiked by 96.02% to -$99,000 in 2021, then skyrocketed by 1,854.55% to $1.7 million in 2022, then spiked by 1,781.87% to $32.7 million in 2023, then tumbled by 185.47% to -$27.9 million in 2024.